

# POTELIGEO® (mogamulizumab-kpkc) **Patient Assistance Program Application**

Email: patientservices@kyowakirincares.com | Phone: 833-KK-CARES (833-552-2737) Fax: 844-267-5848 | Hours: M-F, 8 AM to 8 PM ET

# Please complete application in full, sign and date, and fax to 844-267-5848

- This Patient Assistance Program (PAP) Application must be completed in order to be reviewed for program eligibility. Please ensure the form is completed in full, including all signatures
- To be considered for the PAP, all applicants must satisfy the following requirements and eligibility criteria:
  - o Applicants must complete the Patient Financial Information section below, attach proof of income, and must qualify for the program financial requirements
  - Applicants must be permanent United States (US) resident (including all US Territories)
  - Applicants must be fully uninsured (no health insurance or prescription drug insurance whatsoever)
  - o The requested product must be prescribed by a licensed US healthcare professional for the Food and Drug Administration (FDA) approved indication
- Each applicant will be individually assessed for program eligibility based on the information provided within this application
- Applicants will only be evaluated for eligibility upon receipt of a completed and signed Kyowa Kirin Cares PAP Application
- Patients with special circumstances such as financial and/or medical hardship that do not meet all of the PAP eligibility criteria, as determined in accordance with Kyowa Kirin Cares criteria, may submit an exception request for review. The decision to grant an exception is made at the sole discretion of Kyowa Kirin Inc, and is based on an individual's unique circumstances



#### POTELIGEO® (mogamulizumab-kpkc) Patient Assistance Program Application

Email: patientservices@kyowakirincares.com | Phone: 833-KK-CARES (833-552-2737) | Fax: 844-267-5848 | Hours: M-F, 8AM to 8PM ET

cares

	_	Da	41/	ent
		ГС	llit	fiil
· ·				



Once pages 2, 3, and 4 of the enrollment form are fully completed and signed, please email or fax to Kyowa Kirin Cares.

,								
	Patient Information	on						
	First Name:			e:			DOB:	//
	Last 4 SSN:							
(2	Address:							
	Cell Phone: ()							
	OK to Text?: By checking I receive ma	this box, I confirm this is my pho y vary based on the progress of	one number and agree to s fmy enrollment.	subscribe to the	e Kyowa Kirin Cares	Text Message progra	m. I understand the	amount of texts
	Preferred Contact Method	: Cell Phone Ho	me Phone	il	Best Time to C	all: Morning	Afternoon	Evening
	Patient Financial	Information						
	(Documented Proof of	Income is required if p	atient does not sig	gn Electror	nic Income Ver	ification Autho	rization)	
Ç	Total Annual Gross House	hold Income: \$		N	umber of People	in Household:		
	☐ No Household Income	(\$0 – Provide a notarized	d signed letter from t	the patient e	explaining zero i	ncome) 🗆 Othe	r:	
(	Prescriber Inform	nation						
	Prescriber Name:					Drocoribor N	IDI #·	
	Prescriber DEA:							
	Facility Name:							
Y	Facility Address:							
	Primary Office Contact:							
	Phone Number: ()							
L	Filotie Nutriber. ()	Office	Contact Email.					
	Clinical Informati	on						
	Primary Diagnosis Code (I	CD-10):		Primary [	Diagnosis Descrip	otion:		<del> </del>
	Allergies:							
L								
	Prescription for F	POTELIGEO® (mo	ogamulizumal	b-kpkc)				
	Rx: POTELIGEO (mogar	<b>nulizumab-kpkc)</b> – 20m	g per 5mL		Patient Weight:_		kg Refills:	
	☐ Initiating Therapy – 1m	g/kg IV QW for the first 5	infusions	enance – 1	m/kg IV QOW	Other (write	in below)	
	Rx Notes:							
C	I certify that the information provided according to the approved indication, and that I will supervise the patient's information to Kyowa Kirin and their insurance coverage status, to assess understand the application to the Profinancial and/or insurance status chapatient's insurance status. I agree the to prescribe any Kyowa Kirin product out submit claims or make any attempatient information relating to POTEL and disclose as necessary for verific	Mycosis Fungoides or Sézary Syn medical treatment. I certify that I agents and representatives. I und, if applicable, patient's eligibility for gram does not guarantee that assis inges, the patient may no longer but Kyowa Kirin Cares may contact mt and that I have not received, nor pt to receive reimbursement for proc. IGEO therapy to agents, and servi-	ndrome, subtypes of cutaneous have obtained from my patie lerstand that any information reparticipation in the Kyowa K stance will be obtained. I und e eligible for the Program, are for additional information rewill I receive any benefit fror duct provided by the Prograr ce providers of Kyowa Kirin (	us T-cell lympho  int all required w  n provided is for  firin Cares Patier  lerstand that Kychol I agree to imrelating to this app  m Kyowa Kirin o  m. By signing thi  (including but no)	ma (CTČL), who have rither authorizations fo the sole use of Kyowe at Assistance Program owa Kirin may change on mediately notify a Kyow blication either by fax, e tr their agents or repres s Patient Assistance Pr Li limited to AllCare Plus Li mited to AllCare Plus	relapsed or are refractor the release of my pat Kirin and their agents ("the Program"), and to or cancel this program a ra Kirin Cares represer -mail, and/or telephone entatives for prescribir orgram Application, I au Pharmacy, LLC and P	ny after at least one pient's personal identifier and representatives otherwise administer at any time. I understattative if I become awa. I understand that I ag a Kyowa Kirin procuthorize the release of OTELIGEO-dispensir	vior systemic therapy, ication and insurance to verify my patient's the related services. I and that if my patient's rare of changes in the m under no obligation duct. I agree that I will f medical and/or other
HCP Sign	Prescriber Signature:						Date:	
						official state prescript	ion forms	



#### POTELIGEO® (mogamulizumab-kpkc) Patient Assistance Program Application

Email: patientservices@kyowakirincares.com | Phone: 833-KK-CARES (833-552-2737) | Fax: 844-267-5848 | Hours: M-F, 8AM to 8PM ET

Patient First and Last Name:

Once pages 2, 3, and 4 of the enrollment form are fully completed and signed, please email or fax to Kyowa Kirin Cares.

#### Patient Authorization and Agreement

By signing this Authorization, I authorize each of my prescribers, pharmacists, including any specialty pharmacy that receives my prescription for POTELIGEO (mogamulizumab-kpkc) and other healthcare providers (together "Healthcare Providers") and each of my health insurers (together, "Insurers") to disclose my Protected Health Information, including but not limited to medical records, information related to my medical condition and treatment, my health insurance coverage, my name, address, telephone number, Social Security number, insurance plan and or group numbers (together, "Protected Health Information") to Kyowa Kirin, its affiliated companies, vendors, agents, collaboration partners, and representatives (together, "Kyowa Kirin") including providers of alternate sources of funding for prescription drug costs, and other service providers supporting Kyowa Kirin Cares Patient Assistance (the "Program") for Healthcare Providers and patients for the purposes described below. Specifically, I authorize disclosure of my Protected Health Information in order to:

- Ι. Enroll me in, and contact me about the Program, including online support, financial assistance services, co-pay assistance, specialist services, and compliance and persistency services
- II. Communicate with my Healthcare Providers and Insurers about benefits, coverage and medical care, including compliance with Product treatments
- III. Locate a specialty pharmacy that can fill my prescription and facilitate dispensing of my prescription by such pharmacy
- IV. Provide me with educational materials, information and services related to my treatment experience with POTELIGEO and my condition
- V. Contact me and leave messages about my use of POTELIGEO and my medical care
- VI. Verify, investigate, assist with, and coordinate my coverage for POTELIGEO with my Insurers
- VII. Coordinate prescription fulfillment
- VIII. Contact me as otherwise required or permitted by law

Once my Protected Health Information has been disclosed to Kyowa Kirin, I understand that federal privacy laws no longer protect the information. However, Kyowa Kirin agrees to protect my Protected Health Information by using and disclosing it only for the purposes described in this authorization or as permitted by law. I understand that I may refuse to sign this Authorization. My choice about whether to sign will not change the way my Healthcare Providers or Insurers treat me, but

I will not have access to the Kyowa Kirin Cares Program and the services provided by Kyowa Kirin under the Program. If I refuse to sign the Authorization, or revoke my authorization at a later time, I understand that this means I will not be able to participate or receive assistance from the Program.

I understand that I may cancel this Authorization at any time in the future, except to the extent that actions have been taken in reliance on the authorization, by mailing a request to 510 Carnegie Center, Suite 600 Princeton, NJ 08540, via fax at 844-267-5848, or by calling 833-552-2737. I understand that revoking this Authorization will end further uses and disclosure of my Protected Health Information by the parties identified above except to the extent those uses and disclosures have been made in reliance upon this Authorization as permitted by applicable law. I am entitled to receive a copy of this Authorization.

I understand that if I qualify and I am enrolled in the Program sponsored by Kyowa Kirin, I will receive POTELIGEO from Kyowa Kirin only pursuant to a legally valid prescription from my health care provider. I understand that if I qualify and I am enrolled in the Program, Kyowa Kirin will provide me POTELIGEO free of charge for the duration of the enrollment period so long as I have a legally valid prescription for POTELIGEO. I understand that I am not required to continue treatment with POTELIGEO if I gain insurance coverage, or to receive treatment from any given provider. I understand and agree that I must notify Kyowa Kirin Cares at 833-KK-CARES immediately if my insurance status changes during the Program enrollment period. I understand and agree that neither I nor my Insurers, if applicable, will be charged for the supply of POTELIGEO that I received from the Program, and that under NO circumstances may I claim reimbursement from my Insurers or any related third party for the POTELIGEO provided to me free of charge from the Program. I understand that Kyowa Kirin reserves the right at any time without notice to modify or discontinue the Program and its criteria.

I understand that I am providing 'written instructions' to Kyowa Kirin and its vendor Sonexus Health, LLC under the Fair Credit Reporting Act authorizing AllCare Plus Pharmacy, LLC on behalf of Kyowa Kirin to obtain information from my credit profile or other information from Experian Health. I authorize Kyowa Kirin and its partnered provider AllCare Plus Pharmacy, LLC to obtain such information solely for the purpose of determining financial qualifications for the Program. I understand that I must affirmatively agree to the terms in this notice by signing below in order to proceed in the Program financial screening process.

My signature certifies that I have read and understand the above statements, and agree to the outlined terms.

communications from Kyowa Kirin, including information about opportunities to participate in market research. Checking this box is not a requirement medicine or Kyowa Kirin Cares services.	
Patient Name (Print):	
Patient Signature:	



## POTELIGEO® (mogamulizumab-kpkc) Patient Assistance Program Application

Email: patientservices@kyowakirincares.com | Phone: 833-KK-CARES (833-552-2737) | Fax: 844-267-5848 | Hours: M-F, 8AM to 8PM ET

F	atient First and Last Name: DOB://
	Once pages 2, 3, and 4 of the enrollment form are fully completed and signed, please email or fax to Kyowa Kirin Cares.
(	Patient Authorized Representative
	I permit Kyowa Kirin Cares support services representatives to speak with the following person about this enrollment form. This includes discussing the status of my application, insurance and financial questions, any missing documentation and other issues related to my enrollment, insurance appeals, or any other treatment related issues. I may cancel this authorization at any time by calling: 833-552-2737.
	Name of Authorized Representative: Relationship to Patient:
	Telephone Number: ()Email:
	By signing below, I, the patient, allow this representative to speak on my behalf on any matter regarding my enrollment with the Program.
er	Patient Signature:Date:







POTELIGEO is a prescription medicine used to treat mycosis fungoides (MF) or Sézary syndrome (SS) in adults who have tried at least one prior medicine (taken by mouth or injection) that did not work or in whom the disease has come back.

### Important Safety Information

owa Kirin core

What is the most important information I should know about POTELIGEO?

POTELIGEO may cause serious side effects that can be severe or life-threatening including skin problems, infusion reactions, infections, autoimmune problems, and complications from stem cell transplant.

Call or see your healthcare provider right away if you develop any symptoms of the following problems or if these symptoms get worse:

- Skin problems: Signs and symptoms of skin reactions may include skin pain, itching, skin blistering or peeling, rash, painful sores or ulcers in your mouth, nose, throat or genital area.
- Infusion reactions: Signs and symptoms of infusion reactions may include chills or shaking, redness on your face (flushing), itching or rash, shortness of breath, coughing or wheezing, dizziness, feeling like passing out, tiredness, fever.
- Infections: Signs and symptoms of infection may include fever, sweats or chills, nausea, flu-like symptoms, sore throat or difficulty swallowing, shortness of breath, diarrhea or stomach pain, cough.
- · Autoimmune problems: Some people receiving POTELIGEO may develop autoimmune problems, and some people who already have an autoimmune disease may get worse during treatment with POTELIGEO.
- Complications of stem cell transplant: Patients who receive a stem cell transplant using donor stem cells (allogeneic) after treatment with POTELIGEO may experience complications that can be severe and lead to death. Your healthcare provider will monitor you for signs of complications if you have an allogeneic stem cell transplant.

#### What are the most common side effects of POTELIGEO?

The most common side effects of POTELIGEO include rash, tiredness, diarrhea, muscle and bone pain, and upper respiratory tract infection.

#### Before starting POTELIGEO treatment, tell your doctor about all your medical conditions, including whether you:

- have had a severe skin reaction after receiving POTELIGEO
- have had an infusion reaction during or after receiving POTELIGEO
- have or have had liver problems including hepatitis B (HBV) infection
- have a history of autoimmune problems
- have undergone or plan to have a stem cell transplant, using cells from a donor
- have lung or breathing problems
- · are pregnant or plan to become pregnant
  - It is not known if POTELIGEO will harm your unborn baby
- are breastfeeding or plan to breastfeed
  - Talk to your healthcare provider about the best way to feed your baby during treatment with POTELIGEO

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full <u>Prescribing Information</u> as well as <u>Patient Information</u>.

